Neurizon Therapeutics Limited has released a press release.
ONJCRI Evaluates Monepantel Anti-Cancer Mechanism
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PAA Evaluate MPL Suitability for Ex-Vivo Human COVID-19 Test
- PAA awarded grant for Phase I trial in Motor Neurone Disease
- PharmAust Shareholder Update
- Monepantel Anti-viral Activity Against SARS-CoV-2 Confirmed
- Elanco Option Update
Later from Neurizon Therapeutics
- PharmAust to Commence Phase IIb Dog Cancer Trial
- PAA Commences Manufacture of GMP-Grade MPL for Human Trials
- PAA & ONJCRI to Continue MPL Pre-clinical Investigations
- Leiden University Medical Centre Monepantel COVID-19 Testing
- Epichem Awarded $200K WasteSorted e-Waste Grant
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics